Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Valneva ( (VALN) ) is now available.
Valneva SE announced positive results from its Phase 1 clinical trial of VLA1601, a second-generation adjuvanted inactivated vaccine candidate against the Zika virus. Conducted in the United States with approximately 150 participants, the trial demonstrated that VLA1601 was generally safe and well tolerated, with no safety concerns identified. The strongest immune response was observed in the double-adjuvant treatment arms, showing significantly higher neutralizing antibody titers compared to the single-adjuvant arm. These results indicate an improved immune response over the first-generation vaccine candidate, but further development will depend on securing major funding opportunities.
The most recent analyst rating on (VALN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects a mix of positive technical momentum and strategic progress in vaccine development, offset by financial challenges. The company’s strong cash position and revenue growth are promising, but negative profitability and valuation metrics weigh on the score.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions, with a strong track record of advancing multiple vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is involved in developing vaccine candidates against Lyme disease, Shigella, Zika virus, and other global public health threats.
Average Trading Volume: 87,513
Technical Sentiment Signal: Buy
Current Market Cap: $770.5M
See more insights into VALN stock on TipRanks’ Stock Analysis page.